help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-2222
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/6/2295    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gambineri, A.
Right arrow Articles by Walker, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gambineri, A.
Right arrow Articles by Walker, B. R.
Related Collections
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 6 2295-2302
Copyright © 2006 by The Endocrine Society

Genetic Variation in 11ß-Hydroxysteroid Dehydrogenase Type 1 Predicts Adrenal Hyperandrogenism among Lean Women with Polycystic Ovary Syndrome

Alessandra Gambineri, Valentina Vicennati, Silvia Genghini, Federica Tomassoni, Uberto Pagotto, Renato Pasquali and Brian R. Walker

Division of Endocrinology (A.G., V.V., S.G., F.T., U.P., R.P.), Department of Internal Medicine, and Centre for Applied Biomedical Research, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy; and Endocrinology Unit (B.R.W.), Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh EH8 9AG, United Kingdom

Address all correspondence and requests for reprints to: Alessandra Gambineri, M.D., Division of Endocrinology, Department of Internal Medicine, S. Orsola-Malpighi Hospital, via Massarenti 9, 40138 Bologna, Italy. E-mail: gambineri{at}aosp.bo.it.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: Elevated adrenal androgen levels are common in polycystic ovary syndrome (PCOS), but the underlying pathogenetic mechanism is poorly understood. In the rare cortisone reductase deficiency, impaired regeneration of active cortisol from inert cortisone by 11ß-hydroxysteroid dehydrogenase (11ß-HSD1) results in compensatory activation of ACTH secretion and adrenal hyperandrogenism. 11ß-HSD1 deficiency may protect against obesity and its metabolic consequences because of impaired regeneration of cortisol in adipose tissue.

Objective: Our objective was to investigate a functional polymorphism in HSD11B1 (T->G in the third intron rs12086634, which associates with lower 11ß-HSD1 activity) in PCOS with and without obesity.

Design and Setting: We conducted a case-control study in lean and obese PCOS patients and controls at an academic hospital.

Participants: Participants included 102 Caucasian PCOS patients and 98 controls comparable for age, weight, and race.

Main Outcome Measures: We assessed genotype distribution and influence of genotypes on clinical, hormonal, and metabolic parameters.

Results: The G allele was significantly related to PCOS status (P = 0.041), and this association was mainly attributable to lean (P = 0.025), rather than obese (P = 0.424), PCOS patients. The G allele was associated with lower 0800–0830 h plasma cortisol (P < 0.001) and higher cortisol response to ACTH1–24 (P < 0.001) in all women with PCOS and with higher dehydroepiandrosterone sulfate levels (P < 0.001), greater suppression of dehydroepiandrosterone sulfate by dexamethasone (P < 0.001), and lower fasting plasma low-density lipoprotein cholesterol (P = 0.002) levels in lean PCOS women.

Conclusions: Genetic variation in 11ß-HSD1 contributes to enhanced cortisol clearance and compensatory adrenal hyperandrogenism in lean patients with PCOS but may be protective against obesity and some features of the metabolic syndrome.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
THE ENZYME 11ß-HYDROXYSTEROID dehydrogenase type 1 (11ß-HSD1) converts the inactive steroid cortisone into the active glucocorticoid cortisol, principally in liver and adipose tissue. This provides a mechanism for tissue-specific control of corticosteroid receptor activation which is independent of circulating cortisol concentrations (1, 2). 11ß-HSD1 seems to be important in metabolic disease, because in mice, increasing enzyme activity in adipose tissue enhances local glucocorticoid levels and produces a metabolic syndrome (3), whereas decreasing enzyme activity protects against obesity and the metabolic syndrome (4, 5). In humans, 11ß-HSD1 expression is increased in adipose tissue in obesity (6), whereas inhibition of 11ß-HSD1 enhances insulin sensitivity and provides a new approach to treat type 2 diabetes (7, 8, 9).

Polymorphisms in the HSD11B1 gene, which encodes 11ß-HSD1, have been associated with type 2 diabetes (10) and hypertension (11). A T->G polymorphism in the third intron (rs12086634) is protective against diabetes in Pima Indians (10). This polymorphism reduces HSD11B1 gene transcription in vitro (12), which is consistent with reduced cortisol generation within cells. However, when regeneration of cortisol in peripheral tissues is impaired, the overall metabolic clearance rate for cortisol is increased. Although any tendency for plasma cortisol concentrations to fall is compensated for by reduced negative feedback suppression of ACTH and hence increased adrenal cortisol secretion, this compensation occurs at the expense of increased ACTH-dependent adrenal androgen secretion. These mechanisms appear to operate in the rare syndrome of cortisone reductase deficiency, characterized by an inability to convert cortisone to cortisol (12, 13). This syndrome has been associated with the T->G polymorphism in the third intron (rs12086634), and female patients affected by cortisol reductase deficiency present with hyperandrogenism and a phenotype resembling polycystic ovary syndrome (PCOS) (hirsutism, irregular menses, and polycystic ovaries) (12, 13).

In patients with PCOS, lower ratios of cortisol/cortisone metabolites in urine have been reported (14), suggesting a reduced 11ß-HSD1 activity, albeit that this may be confounded by coexistent obesity.

These findings highlight the rs12086634 T->G HSD11B1 polymorphism as a candidate to explain the adrenal androgen excess in PCOS. However, any reduction in 11ß-HSD1 might paradoxically protect against obesity and associated metabolic dysfunction. We therefore hypothesized that the T->G HSD11B1 genotype would be enriched only in the subgroup of PCOS patients with adrenal androgen excess in whom hyperandrogenism is not associated with obesity and the metabolic syndrome; the association of these features is frequent, but not universal, in this heterogeneous condition (15, 16, 17). To test this hypothesis we characterized the T->G polymorphism in the third intron of HSD11B1 gene (rs12086634) and its association with hormonal and metabolic phenotype in women with PCOS who were either lean or obese.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Subjects

We investigated 102 unmedicated Caucasian women with PCOS, aged 18–45 yr, and 98 controls comparable for age, weight, and race. PCOS women had polycystic ovarian morphology at ultrasound and at least one of the following: chronic oligo-anovulation, with luteal serum progesterone less than 2 ng/ml (18), 100%; hirsutism with a Ferriman-Gallwey score of at least 8 (19), 68%; and elevated serum testosterone levels more than 2 SD above our reference mean values (20), 51%, according to the Rotterdam consensus (21). Hyperprolactinemia, Cushing’s syndrome, congenital adrenal hyperplasia, and androgen-secreting tumors were excluded by specific laboratory analysis (22). Controls had normal ovaries by ultrasound, no signs of hyperandrogenism, and regular and ovulatory menstrual cycles. Ovulation was documented by the presence of progesterone levels above 8 ng/ml during the luteal phase of the menstrual cycle, tested during the recruitment period (18). To better analyze the impact of obesity on T->G HSD11B1 genotype, we included only lean or obese subjects, excluding overweight women. The degree of obesity was established depending on the body mass index (BMI), and women were classified as lean if BMI was not more than 25 kg/m2 and obese if BMI was at least 30 kg/m2 (23). The protocol was approved by the local ethics committee, and written informed consent was obtained from each patient and control.

Assessment program

Standard anthropometric data (height, weight, and waist circumference) and an L4–L5 computerized tomography scan of body fat distribution (to estimate total, visceral, and sc adipose tissue areas) were obtained from each subject. Moreover, basal blood samples for hormonal [total testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEA-S), SHBG, and cortisol] and metabolic [glucose, insulin, total cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides] determinations were collected at 0800–0830 h after overnight fast. All participants underwent also a fasting 75-g oral glucose tolerance test, an ACTH1–24 stimulation test (250 µg ACTH1–24 iv at 0800–0830 h with blood taken at 0 and 60 min), and a dexamethasone suppression test (0.5 mg orally every 6 h for 4 d with blood taken at 0800–0830 h on the fifth day). Samples were immediately chilled on ice and centrifuged; serum was stored at –20 C and plasma at –80 C until assayed. Studies were performed between d 5 and 10 of the menstrual cycle, or during amenorrhea, after excluding pregnancy by appropriate testing.

Biochemical assay

The assays employed for biochemical measurements have been reported elsewhere (22, 24, 25). Low-density lipoprotein (LDL)-cholesterol was calculated by the Friedewald equation (26). Insulin resistance was estimated using the quantitative insulin-sensitivity check index (QUICKI) and the insulin sensitivity index during the oral glucose tolerance test (ISI) (27, 28).

Genetic analysis

Blood samples were collected in tubes containing disodium-EDTA as anticoagulant and stored at 4 C until extraction. DNA was extracted using QIAGEN silica gel-based spin columns (QiaAmp DNA blood mini kit; QIAGEN, Hilden, Germany). DNA obtained gave a 260/280 absorbance ratio of 1.6–2.0, indicating high-quality DNA. Then samples were loaded in wells made in agarose gel 1% for separation by electrophoresis, to verify the DNA integrity and stored at –20 C until analysis. Genotyping of rs12086634 was performed by allelic discrimination real-time PCR on a TaqMan 7900 HT (Applied Biosystems, Foster City, CA) with probe sequences FAM CAGATGATTTCT and VIC CCCAGAGGATTTCT, forward primer 5'-GGAGGAGAATGGGAAAGGTATCAAC-3', and reverse primer 5'-TCCTCCTGCAAGAGATGGCTATATT-3'. Real-time PCR allelic discrimination was unsuccessful in 19 subjects, who were genotyped by direct sequencing using Big Dye Terminator and an automated capillary sequencer (3730 DNA analyzer; Applied Biosystems), using the forward primer 5'-TGAGCAATCTCTCATTTAAGCCC-3' and reverse primer 5'-TGTCCCTGTCCCACTTACCAGCC-3'. To evaluate whether real-time PCR and direct sequencing were comparable, we analyzed 10 samples with both techniques and obtained the same results.

Power analysis

The number of cases to be included in the study was calculated taking into account a G allele frequency in rs12086634 of 14% in the control Caucasian population (12) and assuming a frequency of 35% in PCOS (estimated from the frequency of adrenal hyperandrogenism in this disorder) (29); a case-control study of 200 subjects has a power of 90% to detect this difference at a significance level of P < 0.05.

Statistical analysis

Data are shown as means ± SD and frequencies. The data were evaluated by means of two-way ANOVA to analyze the overall effect of PCOS and of obesity in the entire population (each adjusted for the other) and to evaluate the interactions between them. The effects within groups were evaluated using the nested design of the two-way ANOVA. Two-way ANOVA with the same design was also applied to analyze the effects of T/G+G/G HSD11B1 genotype (rs12086634) and of obesity. Univariate and multivariate logistic regressions were used to relate the frequency of T/G+G/G HSD11B1 genotype (rs12086634) with the presence of PCOS and with the degree of obesity. The odds ratios (OR) evaluated by the logistic regression, together with their 95% confidence intervals (CI), were also reported. No post hoc analysis was performed. Statistical analyses were performed by running the SPSS/PC+ version 8 (Chicago, IL) software package. Two-tailed P values < 0.05 were considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Influence of PCOS and obesity on clinical, hormonal, and metabolic parameters

Table 1Go shows clinical and biochemical characteristics in PCOS and controls, according to BMI (lean and obese), whereas Table 2Go shows the effect attributable to PCOS status, to obesity, and to their interaction on all the characteristics analyzed.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Clinical, hormonal, and metabolic characteristics in PCOS women and controls

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Estimated effect of PCOS status, obesity, and their interaction on clinical, hormonal, and metabolic characteristics in the entire population

 
PCOS women and controls were of similar age and had similar BMI and body fat distribution, glucose tolerance, and LDL-cholesterol and triglycerides levels. However, these parameters were significantly higher in obese than lean women in both PCOS patients and in controls.

PCOS women had higher levels of androgens (testosterone, androstenedione, and DHEA-S) and lower levels of SHBG, independently of body weight. However, the difference between PCOS and controls in SHBG levels was more evident in lean than obese subjects.

PCOS women had an exaggerated response of cortisol to ACTH1–24, were more insulin resistant, and had higher insulin responsiveness to the glucose load and lower HDL-cholesterol levels when compared with controls. Insulin resistance and insulin responsiveness to the glucose load were significantly higher, whereas HDL-cholesterol levels were significantly lower in obese than lean women in both PCOS and controls.

No effects of PCOS or obesity on basal cortisol levels, on the responsiveness of androgens to ACTH1–24, and on the suppression of adrenal steroids by dexamethasone were observed.

HSD11B1 genotype (rs12086634) in PCOS women compared with controls

The allelic frequency of the T->G polymorphism (rs1208664) in the third intron of HSD11B1 was 14% in the entire population. Sixty-seven percent (n = 68) of PCOS and 80% (n = 78) of controls were T/T; 33% (n = 34) of PCOS and 18% (n = 18) of controls were T/G; and 0% of PCOS and 2% (n = 2) of controls were G/G. Therefore, the G allele was significantly related to PCOS status, and this association was mainly attributable to lean, rather than obese, PCOS patients (Table 3Go).


View this table:
[in this window]
[in a new window]
  		TABLE 3. Frequency of T/G+G/G HSD11B1genotype (rs12086634) in PCOS women and controls

 
Influence of the T/G+G/G HSD11B1 genotype (rs12086634) on clinical, hormonal, and metabolic characteristics within PCOS and controls

Table 4Go and Figs. 1Go and 2Go show clinical and biochemical characteristics in PCOS women, according to the HSD11B1 genotype (rs12086634) (T/T and T/G+G/G), whereas Table 5Go shows the effect attributable to T/G+G/G HSD11B1 genotype (rs12086634), to obesity, and to their interaction on all the characteristics analyzed within the PCOS group.


View this table:
[in this window]
[in a new window]
  		TABLE 4. Clinical, hormonal, and metabolic characteristics in lean and obese PCOS women according to the HSD11B1genotype (rs12086634)

 

Figure 1
View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1. Fasting plasma DHEA-S (A) and cortisol levels (B), percent change in DHEA-S levels in response to dexamethasone (% {Delta}(5-b) DHEA-S) (C), and percent change in cortisol levels in response to ACTH1–24 (% {Delta}(60–0) cortisol) (D) in lean and obese PCOS women according to the HSD11B1 genotype (rs12086634) (T/T and T/G+G/G). P values refer to the effect of the HSD11B1 genotype (rs12086634) within lean and obese PCOS women. Abbreviations and conversion factors to SI units are described in the legend to Table 1Go.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 2. Fasting plasma LDL-cholesterol levels in lean and obese PCOS women according to the HSD11B1 genotype (rs12086634) (T/T and T/G+G/G). P values refer to the effect of the HSD11B1 genotype (rs12086634) within lean and obese PCOS women. Abbreviations and conversion factors to SI units are described in the legend to Table 1Go.

 

View this table:
[in this window]
[in a new window]
  		TABLE 5. Estimated effect of T/G+G/G HSD11B1genotype (rs12086634) and obesity and their interaction on clinical, hormonal, and metabolic characteristics in the population of PCOS

 
Among women with PCOS, the G allele of rs12086634 was associated with higher DHEA-S, lower 0800–0830 h plasma cortisol, higher cortisol response to ACTH1–24, greater suppression of DHEA-S and androstenedione by dexamethasone, and lower fasting plasma LDL-cholesterol levels (Tables 4Go and 5Go). When we considered the effect of obesity, we found that the associations of the G allele with cortisol and its response to ACTH1–24 were significant in all PCOS women, independently of body weight, whereas associations with elevated DHEA-S concentrations and greater DHEA-S suppression after dexamethasone administration were significant in lean rather than obese PCOS women (Fig. 1Go and Table 5Go). The HSD11B1 rs1208664 genotype did not predict body fat distribution, insulin sensitivity, or glucose tolerance, although the G allele was associated with lower fasting plasma LDL-cholesterol in PCOS, particularly in lean PCOS women (Fig. 2Go and Table 5Go). Among control subjects, HSD11B1 rs1208664 genotype had no influence on any of the clinical, metabolic, and hormonal variables (data not shown).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
This case-control study shows that a polymorphism that predicts lower 11ß-HSD1-dependent peripheral regeneration of cortisol is 1) related to PCOS status, 2) associated with lower morning cortisol values and increased adrenal cortisol response to ACTH (consistent with compensatory activation of the hypothalamic-pituitary adrenal axis in response to an enhanced metabolic clearance rate for cortisol) in PCOS, and 3) associated with increased adrenal hyperandrogenism and with a protective serum lipid profile (lower LDL-cholesterol levels) in lean PCOS. These data linking genotype with both intermediate phenotype and disease prevalence strongly support a role for the HSD11B1 gene in the pathogenesis of PCOS, at least in a subgroup of patients.

The association of the HSD11B1 genotype with PCOS was mainly attributable to lean, rather than obese, PCOS patients; lean patients are relatively enriched in this study cohort by the selection criteria for lean and obese groups. The lack of overweight subjects (BMI, 26–29 kg/m2) distinguishes this study from that of San Millán et al. (30), performed in another population of Caucasian women, in which no association between HSD11B1 genotype and PCOS was found. In addition, ovarian morphology was not used in the diagnostic criteria by San Millán et al. (30), suggesting that different populations of PCOS and control subjects were included in the two studies and reinforcing that HSD11B1 polymorphisms may be relevant only in some subgroups of this heterogeneous condition. Also, data from White (31) did not show association between HSD11B1 genotype and PCOS. However, these data were from a multiethnic population, and the criteria used by the author to diagnose PCOS (only presence of more than 10 cysts detected by magnetic resonance imaging in one or both ovaries) are inadequate, because they are not in accordance with the diagnostic criteria recommended either by the National Institutes of Health (32) or the Rotterdam Consensus (21).

The finding of an association of HSD11B1 genotype with adrenal hyperandrogenism only in lean PCOS women suggests that in obese PCOS women, adrenal hyperandrogenism must have a different pathogenetic mechanism. This might involve abnormal adrenal steroidogenesis as a consequence of hyperinsulinemia (33) or may also be related to increased cortisol clearance, because obese patients have increased metabolic clearance of cortisol by 5{alpha}-reductase (34).

Among PCOS women, the apparent lower prevalence of rs1208664 T->G in the obese than lean patients also suggests that this genotype either reduces the chances of becoming obese or reduces the chance of developing PCOS in the presence of obesity. This could be attributed to lower intracellular cortisol levels, particularly in adipose tissue and liver, which are protective against features of the metabolic syndrome (1, 2). This is supported by the atheroprotective lipid profile observed in lean PCOS women carrying the G allele.

However, contrary to our expectations, we did not find any association of the HSD11B1 genotype with measures of insulin sensitivity. This result is in accordance with the study performed by San Millán et al. (30) but in apparent contrast with a previous report obtained in a large population of Pima Indians (10). This discrepancy might be attributed to ethnic and environmental differences between the cohorts or to the different methods used to asses insulin sensitivity. The principal association in the Pima Indians was with insulin sensitivity in a euglycemic hyperinsulinemic clamp rather than with fasting insulin levels and insulin responses to a glucose load, the methods used by us and by San Millán et al. (30 ).

The lack of association of HSD11B1 genotype with biochemical phenotype in control subjects may reflect the lack of statistical power or the presence of modifying environmental or genetic factors.

In conclusion, genetic variation in 11ß-HSD1 may underlie adrenal hyperandrogenism in lean patients with PCOS but may protect against obesity and associated metabolic dysfunction. These observations lend additional support to the concept that the pathogenesis of PCOS is different among the different phenotypes of the syndrome.


   Acknowledgments
 
We thank Dr. Antonio Maria Morselli-Labate for statistical analysis and Dr. Stuart Bayliss, Dr. Caroline Hayward, and the Welcome Trust Clinical Research Facility for genotyping.


   Footnotes
 
This work was supported by the British Heart Foundation and by a grant from the Sixth European Community Program (LSHM-CT-2003-503041).

The authors have nothing to declare.

First Published Online March 21, 2006

Abbreviations: BMI, Body mass index; CI, confidence interval; DHEA-S, dehydroepiandrosterone sulfate; HDL, high-density lipoprotein; 11ß-HSD1, 11ß-hydroxysteroid dehydrogenase; ISI, insulin sensitivity index; LDL, low-density lipoprotein; OR, odds ratio; PCOS, polycystic ovary syndrome; QUICKI, quantitative insulin-sensitivity check index.

Received October 7, 2005.

Accepted March 13, 2006.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Seckl JR, Walker BR 2001 11ß-Hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371–1376[Abstract/Free Full Text]
  2. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11ß-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831–866[Abstract/Free Full Text]
  3. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166–2170[Abstract/Free Full Text]
  4. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11ß-hydroxysteroid dehydrogenase 1 null mice. J Biol Chem 276:41293–41300[Abstract/Free Full Text]
  5. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11ß-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931–938[Abstract/Free Full Text]
  6. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11ß-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330–3336[Abstract/Free Full Text]
  7. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155–3159[Abstract]
  8. Andrews RC, Rooyackers O, Walker BR 2003 Effects of the 11ß-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285–291[Abstract/Free Full Text]
  9. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR 2005 Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11ß-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872–879[Abstract/Free Full Text]
  10. Nair S, Lee YH, Lindsay RS, Walker BR, Tatarani PA, Bogardus C, Baier LJ, Permana PA 2004 11ß-Hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 47:1088–1095[Medline]
  11. Franks PW, Knowler WC, Nair S, Koska J, Lee YH, Lindsay RS, Walker BR, Looker HC, Permana PA, Tatarani PA, Hanson RL 2004 Interaction between an 11ßHSD1 gene variant and birth era modifies risk of hypertension in Pima Indians. Hypertension 44:681–688[Abstract/Free Full Text]
  12. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CHL, Stewart PM 2003 Mutations in the gene encoding 11ß-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34:434–439[CrossRef][Medline]
  13. Phillipov G, Palermo M, Shackleton CH 1996 Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 81:3855–3860[Abstract/Free Full Text]
  14. Rodin A, Thakkar H, Taylor NJ, Clayton R 1994 Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11ß-hydroxysteroid dehydrogenase. N Engl J Med 330:460–465[Abstract/Free Full Text]
  15. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935[Abstract/Free Full Text]
  16. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictions of the risk of type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169[Abstract/Free Full Text]
  17. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R 2004 Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Diabetes 53:2353–2358[Abstract/Free Full Text]
  18. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R 1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876–1880[Abstract/Free Full Text]
  19. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447[Medline]
  20. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60:241–249[CrossRef][Medline]
  21. The Rotterdam ESHRE/ASMR-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reprod 19:41–47[Abstract/Free Full Text]
  22. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognini GE, Filicori M, Morselli-Labate AM 2000 Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774[Abstract/Free Full Text]
  23. World Health Organization1997 Preventing and managing the global epidemic of obesity: report of the World Health Organization consultation on obesity. Geneva: World Health Organization
  24. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM 1999 The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 50:517–527[CrossRef][Medline]
  25. Vicennati V, Pasquali R 2000 Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and peripheral alteration. J Clin Endocrinol Metab 85:4093–4098[Abstract/Free Full Text]
  26. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502[Abstract]
  27. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Kats A, Quon MJ, Baron AD 2001 Repeatability characteristic of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86:5457–5464[Abstract/Free Full Text]
  28. Matsuda M, De Fronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470[Abstract/Free Full Text]
  29. Morán C, Knochenhauer ES, Boots LR, Azziz R 1999 Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 71:671–674[CrossRef][Medline]
  30. San Millán JL, Botella-Carretero JI, Alvarez-Blasco F, Luque-Ramírez M, Sancho J, Moghetti P, Escobar-Morreale HF 2005 A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11ß-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 90:4157–4162[Abstract/Free Full Text]
  31. White PC 2005 Genotypes at 11ß-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J Clin Endocrinol Metab 90:5880–5883[Abstract/Free Full Text]
  32. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific; 377–384
  33. Hines GA, Smith ER, Azziz R 2001 Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies. Fertil Steril 76:730–735[CrossRef][Medline]
  34. Andrew R, Phillips DIW, Walker BR 1998 Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806–1809[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. O. Goodarzi, N. Xu, and R. Azziz
Association of CYP3A7*1C and Serum Dehydroepiandrosterone Sulfate Levels in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2909 - 2912.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Yazawa, M. Uesaka, Y. Inaoka, T. Mizutani, T. Sekiguchi, T. Kajitani, T. Kitano, A. Umezawa, and K. Miyamoto
Cyp11b1 Is Induced in the Murine Gonad by Luteinizing Hormone/Human Chorionic Gonadotropin and Involved in the Production of 11-Ketotestosterone, a Major Fish Androgen: Conservation and Evolution of the Androgen Metabolic Pathway
Endocrinology, April 1, 2008; 149(4): 1786 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet
Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity
Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. O. Goodarzi, H. J. Antoine, and R. Azziz
Genes for Enzymes Regulating Dehydroepiandrosterone Sulfonation Are Associated with Levels of Dehydroepiandrosterone Sulfate in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2659 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Smit, M. J. H. J. Dekker, F. J. de Jong, A. W. van den Beld, J. W. Koper, H. A. P. Pols, A. O. Brinkmann, F. H. de Jong, M. M. B. Breteler, and S. W. J. Lamberts
Lack of Association of the 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Gene 83,557insA and Hexose-6-Phosphate Dehydrogenase Gene R453Q Polymorphisms with Body Composition, Adrenal Androgen Production, Blood Pressure, Glucose Metabolism, and Dementia
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 359 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Corton, J. I. Botella-Carretero, A. Benguria, G. Villuendas, A. Zaballos, J. L. San Millan, H. F. Escobar-Morreale, and B. Peral
Differential Gene Expression Profile in Omental Adipose Tissue in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 328 - 337.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/6/2295    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gambineri, A.
Right arrow Articles by Walker, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gambineri, A.
Right arrow Articles by Walker, B. R.
Related Collections
Right arrow Female Endocrinology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals